Evidence map›Paper›PMID 34314438›Full record

ArticlePloS one2021

Single-cell immunoblotting resolves estrogen receptor-α isoforms in breast cancer.

John J Kim, Wenchuan Liang, Chi-Chih Kang, Mark D Pegram, Amy E Herr

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. ESR1 activating mutations: From structure to clinical application.Biochimica et biophysica acta. Reviews on cancer · 2023
    Review
  5. The Intriguing Landscape of Single-Cell Protein Analysis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

John J KimDepartment of Bioengineering, University of California Berkeley, Berkeley, CA, United States of America.ORCID 0000-0002-4562-3872
Wenchuan LiangDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, CA, United States of America.
Chi-Chih KangDepartment of Bioengineering, University of California Berkeley, Berkeley, CA, United States of America.
Mark D PegramDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, CA, United States of America.
Amy E HerrDepartment of Bioengineering, University of California Berkeley, Berkeley, CA, United States of America.ORCID 0000-0002-6906-2985
University of California, Berkeley · USStanford University · US

Funding

MULTIPLEXED ISOFORM QUANTIFICATION IN HER2-POSITIVE BREAST CANCERR01CA203018 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI HERR, AMY ELIZABETH · 2016 to 2024
$2.8M
Advanced Cancer Classification via Single-Cell Electrophoretic CytopathologyR33CA225296 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI HERR, AMY ELIZABETH · 2017 to 2017
$1.5M
Microfluidic Western Blotting for Targeted Proteomic Analysis of Single Circulating Tumor CellsR21CA183679 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI HERR, AMY ELIZABETH · 2015 to 2017
$634k
NCI NIH HHS R01 CA203018NCI NIH HHS R21 CA183679NCI NIH HHS R33 CA225296
6 · The paper itself

Abstract

An array of isoforms of the nuclear estrogen receptor alpha (ER-α) protein contribute to heterogeneous response in breast cancer (BCa); yet, a single-cell analysis tool that distinguishes the full-length ER-α66 protein from the activation function-1 deficient ER-α46 isoform has not been reported. Specific detection of protein isoforms is a gap in single-cell analysis tools, as the de facto standard immunoassay requires isoform-specific antibody probes. Consequently, to scrutinize hormone response heterogeneity among BCa tumor cells, we develop a precision tool to specifically measure ER-α66, ER- α46, and eight ER-signaling proteins with single-cell resolution in the highly hetero-clonal MCF-7 BCa cell line. With a literature-validated pan-ER immunoprobe, we distinguish ER-α66 from ER-α46 in each individual cell. We identify ER-α46 in 5.5% of hormone-sensitive (MCF-7) and 4.2% of hormone-insensitive (MDA-MB-231) BCa cell lines. To examine whether the single-cell immunoblotting can capture cellular responses to hormones, we treat cells with tamoxifen and identify different sub-populations of ER-α46: (i) ER-α46 induces phospho-AKT at Ser473, (ii) S6-ribosomal protein, an upstream ER target, activates both ER-α66 and ER-α46 in MCF-7 cells, and (iii) ER-α46 partitions MDA-MB-231 subpopulations, which are responsive to tamoxifen. Unlike other single-cell immunoassays, multiplexed single-cell immunoblotting reports-in the same cell-tamoxifen effects on ER signaling proteins and on distinct isoforms of the ER-α protein.

Indexed as

Breast NeoplasmsCell Line, TumorEstrogen Receptor alphaFemaleHumansImmunoblottingPhosphorylationPrincipal Component AnalysisProtein IsoformsProto-Oncogene Proteins c-aktSignal TransductionSingle-Cell AnalysisTamoxifenEstrogen Receptor alphaProtein IsoformsProto-Oncogene Proteins c-aktTamoxifen

Identifiers

PMID34314438
PMCPMC8315538
OpenAlexW3184909617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.